Sumitomo Mitsui DS Asset Management Company Ltd Sells 21,624 Shares of Bristol Myers Squibb Company $BMY

Key Points

• Sumitomo Mitsui DS Asset Management reduced its Bristol Myers Squibb stake by 6.9%, selling 21,624 shares and retaining 292,196 shares valued at approximately $18.2 million. Institutional investors collectively own 76.41% of BMY.
• Analyst sentiment remains mixed but leans positive, with BMY carrying a “Moderate Buy” consensus rating and an average price target of $64.88.
• Bristol Myers Squibb recently beat quarterly earnings and revenue expectations, while maintaining a quarterly dividend of $0.63 per share, equivalent to a roughly 4.1% annual yield.

Sumitomo Mitsui DS Asset Management Company Ltd lessened its position in Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 6.9% in the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 292,196 shares of the biopharmaceutical company's stock after selling 21,624 shares during the quarter. Sumitomo Mitsui DS Asset Management Company Ltd's holdings in Bristol Myers Squibb were worth $18,233,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. CWA Asset Management Group LLC boosted its position in shares of Bristol Myers Squibb by 7.3% in the third quarter. CWA Asset Management Group LLC now owns 192,441 shares of the biopharmaceutical company's stock worth $12,008,000 after buying an additional 13,090 shares during the period. Investment Research Partners LLC grew its holdings in shares of Bristol Myers Squibb by 12.8% during the third quarter. Investment Research Partners LLC now owns 18,834 shares of the biopharmaceutical company's stock valued at $1,175,000 after buying an additional 2,136 shares in the last quarter. Warwick Investment Management Inc. purchased a new position in shares of Bristol Myers Squibb during the third quarter valued at $201,000. Retirement Planning Group LLC raised its position in Bristol Myers Squibb by 17.8% during the third quarter. Retirement Planning Group LLC now owns 9,239 shares of the biopharmaceutical company's stock valued at $577,000 after buying an additional 1,398 shares during the period. Finally, Novem Group raised its position in Bristol Myers Squibb by 4.6% during the third quarter. Novem Group now owns 68,020 shares of the biopharmaceutical company's stock valued at $4,244,000 after buying an additional 3,018 shares during the period. Institutional investors and hedge funds own 76.41% of the company's stock.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the company. Wall Street Zen upgraded Bristol Myers Squibb from a "buy" rating to a "strong-buy" rating in a research report on Saturday, June 27th. Morgan Stanley reiterated an "underweight" rating and issued a $41.00 target price (up from $40.00) on shares of Bristol Myers Squibb in a report on Wednesday, October 7th. Leerink Partners downgraded Bristol Myers Squibb from an "outperform" rating to a "market perform" rating and dropped their target price for the company from $73.00 to $59.00 in a report on Monday, October 5th. JPMorgan Chase & Co. increased their price target on shares of Bristol Myers Squibb from $67.00 to $73.00 and gave the stock an "overweight" rating in a research report on Friday, July 31st. Finally, Zacks Research upgraded shares of Bristol Myers Squibb from a "hold" rating to a "strong-buy" rating in a report on Wednesday, September 23rd. Three investment analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, fifteen have given a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $64.88.

Key Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: RBC expects Bristol Myers Squibb to exceed third-quarter revenue estimates, reinforcing optimism ahead of the company’s earnings report. RBC expects a third-quarter revenue beat for Bristol Myers Squibb stock
• Positive Sentiment: Bristol Myers Squibb is scheduled to present new oncology data at ESMO 2026, including results for pumitamig, izalontamab brengitecan (iza-bren), and the Opdivo-Yervoy combination. Positive data could support the company’s pipeline and long-term growth outlook. Bristol Myers Squibb Heads To ESMO 2026 With New Oncology Data
• Positive Sentiment: Analysts and financial commentators continue to highlight BMY’s relatively low valuation, substantial free-cash-flow generation, and dividend yield of approximately 4.3%. Goldman Sachs also upgraded the stock, adding to bullish sentiment. Amgen vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026? Bristol Myers Squibb Upgraded at The Goldman Sachs Group
• Neutral Sentiment: Investor attention across the pharmaceutical sector is elevated ahead of cancer-drug presentations, with Moderna also attracting buying interest. That broader oncology focus may be helping sentiment toward BMY, although the Moderna catalyst is not directly related to Bristol Myers Squibb. Moderna Jumps While Melanoma Vaccine Data Looms
• Negative Sentiment: The company still faces the challenge of replacing revenue from aging blockbuster medicines. Upcoming ESMO results could either validate its pipeline strategy or increase concerns about future growth. Bristol Myers vs. Eli Lilly: Is BMY’s Deep Valuation Discount Hiding an Opportunity?

Bristol Myers Squibb Stock Up 5.0%

BMY opened at $61.76 on Wednesday. The company has a market capitalization of $126.15 billion, a PE ratio of 13.60, a price-to-earnings-growth ratio of 0.29 and a beta of 0.19. The company has a debt-to-equity ratio of 1.89, a current ratio of 1.53 and a quick ratio of 1.38. Bristol Myers Squibb Company has a fifty-two week low of $42.52 and a fifty-two week high of $68.64. The business has a 50-day moving average of $63.39 and a 200-day moving average of $60.28.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last announced its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 EPS for the quarter, beating the consensus estimate of $1.60 by $0.44. The business had revenue of $12.97 billion during the quarter, compared to analysts' expectations of $11.74 billion. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%. The firm's quarterly revenue was up 5.7% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.46 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. Equities research analysts forecast that Bristol Myers Squibb Company will post 6.77 EPS for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, November 2nd. Investors of record on Friday, October 2nd will be given a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a yield of 4.1%. The ex-dividend date of this dividend is Friday, October 2nd. Bristol Myers Squibb's dividend payout ratio (DPR) is presently 55.51%.

Insider Transactions at Bristol Myers Squibb

In other Bristol Myers Squibb news, SVP Phil M. Holzer sold 500 shares of Bristol Myers Squibb stock in a transaction that occurred on Tuesday, August 25th. The shares were sold at an average price of $67.50, for a total value of $33,750.00. Following the completion of the sale, the senior vice president directly owned 16,862 shares in the company, valued at $1,138,185. The trade was a 2.88% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.05% of the stock is owned by company insiders.

Bristol Myers Squibb Profile

Bristol Myers Squibb NYSE: BMY is a global biopharmaceutical company focused on discovering, developing and commercializing medicines for serious diseases. Its research and development activities span oncology, hematology, immunology, cardiovascular disease, neuroscience and other specialty areas.

The company's portfolio includes oncology medicines such as Opdivo, Yervoy, Abraxane, Sprycel and Pomalyst, as well as Eliquis, an anticoagulant developed in partnership with Pfizer. Bristol Myers Squibb also markets immunology and neuroscience products, including Orencia and Sotyktu, and continues to invest in therapies based on biologics, cell therapy and other advanced treatment approaches.

Bristol Myers Squibb traces its roots to pharmaceutical businesses founded by Bristol-Myers in 1881 and E.R.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol Myers Squibb Company (NYSE:BMY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.